Default company panoramic image
Devicesmall4logo

Veriskin, Inc.

Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location San Diego, CA, USA
  • Currency USD
  • Founded May 2014
  • Employees 3
  • Incorporation Type C-corp
  • Website veriskin.com

Company Summary

The TruScore is a proprietary, non-invasive, low-cost, hand-held device that aids a non-expert user to rapidly and objectively determine whether a suspect skin lesion is cancerous. The patent pending technology works by detecting pathological angiogenesis which is a well established hallmark of cancer. The device is intended to be used as a decision support tool for non-specialists, e.g. primary care physicians and nurse practitioners.

Team

  • Default avatar
    Carl F. Edman
    Co-founder, Board Member

    Experienced early stage medical device executive, co-founder of PhiloMetron (wireless medical devices) and Corventis (acquired by Medtronics $150MM). Strategy and business advisor to multiple entities including Topera (acquired by Abbott $250MM).

  • Default avatar
    Eugene Tu
    Co-founder, Board Member

    Founding team member of multiple biotech startups (Nanogen, Genoptix, Nanomix, Omniome) and consultant to early and growth stage biotech companies. Thirty years’ experience converting research ideas to CLIA and FDA approved products in genomics & diagnostics.

  • Default avatar
    Monica A. Welling, MBA
    VP Commercialization

    DermTech, Allergan, Novo Nordisk

  • Default avatar
    Autumn Lang, Ph.D.
    VP Clinical Affairs

    Edwards Lifesciences, QmedConsulting ApS, coramazetechnologies GmbH, confinisCPM ag, ClinlogixEurope GmbH

Previous Investors